Lv21
130 积分 2024-10-10 加入
An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection
3小时前
待确认
Practical guide to concentration-QTc modeling: a hands-on tutorial
5天前
已完结
Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)
3个月前
已关闭
A Single Administration of the Cytolytic CD38 Antibody TAK-079 to Healthy Subjects: Tolerability, Pharmacokinetics and Pharmacodynamics
3个月前
已关闭
Strategies and Recommendations for Using a Data‐Driven and Risk‐Based Approach in the Selection of First‐in‐Human Starting Dose: An International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) Assessment
3个月前
已完结
An Innovative Approach to Optimize First‐In‐Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T‐Cell Engagers: Experience from A Solid Tumor Bispecific T‐Cell Engager
3个月前
已完结
Mechanism-based pharmacokinetic and pharmacodynamic modeling for bispecific antibodies: challenges and opportunities
3个月前
已完结
Predicting the active doses in humans from animal studies: A novel approach in oncology
3个月前
已完结
Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents
4个月前
已关闭
Translational Model-Based Strategy to Guide the Choice of Clinical Doses for Antibody-Drug Conjugates
4个月前
已完结
皖公网安备34019202002308
